左起依次為：英矽智慧聯席執行長、首席科學官任峰博士，藥明康德高階副總裁、合全藥業原料藥業務部負責人傅小勇博士
中國上海，2022年9月1日 -- 藥明康德子公司合全藥業與端到端人工智慧驅動的藥物研發公司英矽智慧（Insilico Medicine）共同公佈，針對一體化CMC服務簽署戰略合作協議。英矽智慧聯席執行長、首席科學官任峰博士，藥明康德高階副總裁、合全藥業原料藥業務部負責人傅小勇博士，合全藥業高階副總裁、製劑業務負責人陳金玲博士等共同出席了簽約典禮。
英矽智慧是一家由端到端人工智慧（AI）驅動的藥物研發公司，管線籠蓋癌症、纖維化、免疫、中樞神經系統疾病以及朽邁相關疾病等領域，已開發超30條自研管線。其中進展最快的抗纖維化專案ISM001-005目前正在紐西蘭和中國同步開展1期臨床試驗。公司於2021年與合全藥業展開合作，合全藥業為其抗纖維化專案提供了原料藥及製劑的研發和出產端到端支援。
合全藥業作為CRDMO領軍企業，2017年以來已成功支援合作伙伴的35款立異藥獲批，支援的新藥在全球105個國家上市。此次英矽智慧與合全藥業簽署戰略合作協議，是在ISM001-005成功合作的基礎上，進一步拓展雙方合作的深度和寬度。根據戰略合作協議，合全藥業將成為英矽智慧在新藥合同研究、開發與出產領域（CRDMO）的首選合作伙伴，為其在研及後續管線產品提供原料藥及製劑產品的研究、工藝開發、出產、分析以及支援新藥申報的註冊檔案預備等一站式服務。
“我們非常高興藉助合全藥業端到端CMC平臺加快專案進度，雙方過去的合作卓有成效。”英矽智慧創始人兼執行長Alex Zhavoronkov博士表示：”相信此次深化合作，將匡助我們進一步晉升藥物開發的速度和效率，早日滿意迫切的臨床醫療需求。”
“很興奮與英矽智慧強化合作關係。”藥明康德聯席執行長、合全藥業執行長陳民章博士表示：“合全藥業將繼承晉升一體化CRDMO平臺能力，更好地賦能合作伙伴加速立異藥開發，惠及全球病患。”
關於合全藥業
合全藥業是藥明康德子公司，在亞洲、北美及歐洲地區均設有研發及出產基地。合全藥業服務於生命科學行業，擁有卓越的化學立異藥研發和出產的能力和技術平臺。作為全球新藥合同研究、開發與出產領域（CRDMO）的領軍企業，合全藥業致力於為全球合作伙伴提供高效、靈活、高質量的一站式解決方案，以支援包括小分子、寡核苷酸、多肽及各種複雜化學偶聯藥物的研發與出產。更多資訊，請訪問公司網站：www.stapharma.com.cn
WuXi STA Forms Strategic Partnership with Insilico Medicine
From left to right: Insilico Medicine co-CEO and Chief Scientific Officer Dr. Feng Ren, WuXi AppTec Senior Vice President and WuXi STA API Business Head Dr. Xiaoyong Fu
SHANGHAI, CHINA, September 1, 2022 – WuXi STA, a subsidiary of WuXi AppTec, and Insilico Medicine, a global clinical-stage artificial intelligence-driven drug discovery and development company, today announced a strategic partnership for the integrated CMC services.
Insilico Medicine owned more than 30 pipelines under development, covering various diseases, including cancers, fibrosis, immunity, central nervous system diseases, and aging-associated diseases. Insilico’s leading anti-fibrosis drug candidate, ISM001-005, is undergoing phase 1 clinical trials in both New Zealand and China. The collaboration between WuXi STA and Insilico started in 2021, while WuXi STA provided the end-to-end CMC service, including both API and formulation development and manufacturing for ISM001-005.
As the leading CRDMO, WuXi STA has supported 35 new drugs approved globally since 2017, and the products manufactured have been launched in 105 countries. This strategic partnership is to broaden the collaboration between WuXi STA and Insilico beyond ISM001-005. Under this agreement, WuXi STA will be the preferred contract research, development, and manufacturing organization (CRDMO) partner and will provide integrated end-to-end CMC solutions to Insilico’s current and future drug discovery and development projects. The services include but are not limited to API and drug product research, development, manufacturing, and regulatory CMC dossier preparation services.
Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine, commented:“We are excited to have WuXi STA’s end-to-end CMC platform supporting our projects. The past collaboration was fruitful, and I believe this collaboration expansion will greatly accelerate our pipelines to the market and fulfill the patients’ demand around the world.”
Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, commented:“We are pleased to enhance our partnership with Insilico. We will continue building our integrated CRDMO platform and look forward to empowering more breakthroughs to benefit patients worldwide.”
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.
For more information, please visit: http://www.STApharma.com
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.
For more information, visit www.insilico.com
